Q1 2020 & full-year outlook Webcast

6 May 2020





Today's agenda

- Performance
 - o Q1 2020 highlights
 - COVID-19 update
 - Sales trends
 - Financial results
- Strategy update
- 2020 financial outlook
- Q&A session



President & CEO Carsten Hellmann EVP, Group CFO Søren Jelert VP, Head of IR Per Plotnikof

This presentation contains forward-looking statements, including forecasts of future revenue and operating profit, as well as expected business-related events. Such statements are subject to risks and uncertainties, as various factors, some of which are beyond ALK's control, may cause actual results and performance to differ materially from the forecasts made in this presentation. The emergence of the coronavirus pandemic, along with the extent and duration of countermeasures against the virus, represents an additional uncertainty that may also affect forward-looking statements.

Strong Q1 outperforms expectations, guidance kept

- Revenue up 10%; tablet sales up 38% on solid performances from ACARIZAX® and ITULAZAX®
- EBITDA up 49% at DKK 198m on higher sales, operational leverage and lower capacity costs
- FY outlook maintained: 8-12% organic growth still expected in 2020
- Guidance range assumes patients can visit doctors again in H2





ALK

COVID-19 update

No material effect in Q1, subdued growth expected in Q2

Focus is on continued supply of medicines

- Impact expected in Q2, predominantly in SCIT markets, especially in the USA
- Lockdowns restrict visits to doctors. Lost sales may be recovered assuming patients can visits doctors again in H2
- Home-based treatments more resilient; alternative for SCIT patients unable to visit clinics
- Likely delays to clinical trials. Patient recruitment currently paused


No major interruptions to production

Contingency measures in place, inventories robust





Solid sales growth in Europe and Int. markets



North America Share of Q1 revenue 16% **Q1** -4% 150m 2020 2019

International markets




Q1 86m 61m


■2020 ■2019




Tablet sales continue to build momentum



Sales in all markets expressed in DKK Growth rates are organic and in local currencies







Financial robustness improved further in Q1

DKK million	Q1 2019	Q1 2020
Revenue	867	956
Gross profit	532	585
Gross margin	61%	61%
Capacity costs	456	448
EBITDA	133	198
EBIT	76	137
Free cash flow	(17)	21
Cash/credit facilities	975	922



Three-year transformation on track (I)

Succeed in North America Complete and commercialise tablet portfolio Patient engagement and adjacencies

Optimise and reallocate resources

Financial ambitions

An ALK capable of delivering sustainable, high revenue and earnings growth Revenue growth of ≥10% annually Raise margins quickly to specialty pharma levels after 2020

ALK

Three-year transformation on track (II)

Succeed in North America

Full-year target challenged by COVID-19 impact

Targets



Tablets up 22%, overall growth held back by non-allergy products and PRE-PEN[®]

10% growth



Prescriber numbers and prescription depth continue to grow for tablets



Regulatory approval secured in April. Launch plans for H2 on track



engagemen

Digital patient engagement platform launched in early Q2

Complete and commercialise tablet portfolio for all relevant ages

Strong growth trajectory maintained

Targets



Global tablet sales up 38% with ACARIZAX[®] and ITULAZAX[®] leading the way

>30% growth



ITULAZAX[®] roll-out remains on track with additional launches in H2

ITULAZAX® in Europe



Delays in clinical development expected due to COVID-19. Patient recruitment currently paused



Research collaboration with Betamab

Three-year transformation on track (III)

Patient engagement and adjacent business

Digital strategy continues to surpass expectations

Targets



Digital engagement platform launched in Denmark

New markets



~25k mobilised to take action on allergy (searching for/visiting doctor, etc.)

Mobilise 100k patients



Priority given to most suitable AIT candidates during COVID-19 crisis, ahead of high season for new treatment initiations

Optimise and reallocate

Manufacturing robustness continues to improve

Targets



rationalisation

Accelerated programme continued with >300 variants phased out vs. 2016



scalability

ALK continues to raise Jext® production volumes as far as possible to meet demand robustness &



Site specialisation, optimisation efforts and investments in quality continued with the aim of improving long-term efficiency



2020 financial outlook maintained

Expected 2018-20 cash flow burn almost halved due to better sales and earnings (from ~DKK 1bn to ~0.6bn)

DKK	6 May outlook	Comments	2019 actuals
Revenue	+8-12% organic	 Subdued growth in Q2 +30% FY tablet growth -4% p.p. FY impact from portfolio pruning COVID-19: assumes patients can visits doctors again in H2 	3,274m
EBITDA	200-300m	 Gross margin on par with 2019 Lower R&D costs than planned Leveraged sales and marketing platform, unchanged administrative expenses 	241m
Free cash flow	~(300)m	 Subdued earnings due to R&D and strategic investments DKK 250-300 million CAPEX Changes in working capital 	(25)m

Assumptions: Current exchange rates. No revenue from acquisitions and/or partnerships. No sizeable payments for M&A/in-licensing.



Q&A session



Thank you for your attention

7 May: Virtual roadshow, Copenhagen
7 May: <u>Webinar</u>, COVID-19 & allergy
11 May: Virtual roadshow, London
12 May: Virtual roadshow, Frankfurt/Munich
13 May: Virtual roadshow, Milan
19 May: Virtual roadshow, Paris

Investor Relations:

Per Plotnikof, Vice President, Head of Investor Relations Phone: +45 4574 7576 E-mail: ppidk@alk.net Read more: **www.alk.net**



The LIVE webinar will be followed by an open question and answer session.